Jagsonpal Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jagsonpal Pharmaceuticals shareholders have overwhelmingly approved a buy-back of up to 16 lakh (1.6 million) equity shares at ₹250 per share, totaling up to ₹40 crores. The resolution passed with 99.994% votes in favor (48.92 million votes) versus only 2,712 votes against out of 48.92 million valid votes cast. The e-voting period ran from March 26 to April 24, 2026, with 73.06% of total shares participating. Promoter and public categories both voted overwhelmingly in favor. The buy-back price of ₹250 represents a significant premium over the face value of ₹2 per share.
Shareholders who tender their shares in the buy-back will receive ₹250 per share, representing a substantial return of capital. This is positive for shareholders seeking liquidity at a premium price and signals management confidence in the company's financial health.